Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCare PharmaINCPF 83 Days Payable is 285.83 as of Dec. 2025, which is 3% below its 10-year median of 293.89. GuruFocus rates INCPF with a GF Score™ of 83/100 and a GF Value™ of $2.32. The stock has 7 warning signs investors should review. Among 704 Biotechnology companies, InnoCare Pharma ranks better than 71.73% on this metric.
The historical rank and industry rank for InnoCare Pharma's Days Payable or its related term are showing as below:
INCPF'
s Days Payable Range Over the Past 10 Years
Min: 249.98 Med: 293.89 Max: 363.75
Current: 309.39
During the past 9 years, InnoCare Pharma's highest Days Payable was 363.75. The lowest was 249.98. And the median was 293.89.
INCPF's Days Payable is ranked better than 71.73% of 704
companies
in the Biotechnology industry
Industry Median: 110.01
vs INCPF: 309.39
InnoCare Pharma's Days Payable
declined
from Dec. 2024 (286.73) to Dec. 2025 (285.83).
It may suggest that InnoCare Pharmaaccelerated paying its suppliers.
The historical data trend for InnoCare Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INCPF vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, InnoCare Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
InnoCare Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (INCPF) has a Days Payable of 285.83 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InnoCare Pharma and its competitors. This is near median its historical median of 293.89. Over the past decade, InnoCare Pharma's Days Payable has ranged from 249.98 to 363.75. According to the industry distribution chart, InnoCare Pharma ranks #199 out of 704 companies in the Biotechnology industry, placing it in the top 28.3%.
Is InnoCare Pharma's Days Payable too high?
InnoCare Pharma's current Days Payable of 285.83 is near median its 10-year median of 293.89. Over the past 10 years, this metric has ranged from a low of 249.98 to a high of 363.75. The Biotechnology industry median Days Payable is 110.01. InnoCare Pharma's value of 285.83 is 159.8% above this industry median. Based on the distribution chart, InnoCare Pharma ranks #199 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #199 out of 704 companies for Days Payable. This puts InnoCare Pharma in the upper half of its industry. The industry median Days Payable is 110.01. InnoCare Pharma's value of 285.83 is 159.8% above this benchmark. Historically, InnoCare Pharma's own Days Payable has ranged from 249.98 to 363.75 over the past decade. While the company's 10-year median is 293.89 vs. the industry median of 110.01, InnoCare Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCare Pharma's current Days Payable of 285.83 is 159.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InnoCare Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Pharma's current Days Payable is 285.83, which is near median its own 10-year median of 293.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current Days Payable of 285.83. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current Days Payable is 285.83, which is near median its 10-year median of 293.89 and 159.8% above the Biotechnology industry median of 110.01. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current Days Payable is 285.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (INCPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.
Key valuation signals for INCPF:
Days Payable: 285.83 (near median its 10-year median of 293.89)
GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
Industry Position: 159.8% above the Biotechnology median (#199 of 704)
No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for INCPF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCPF has been successfully added to your 
